Drug intelligence / Profile preview

YZD-7082B

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

YZD-7082B is a novel, orally bioavailable selective estrogen receptor degrader (SERD). It has been developed as a potential therapeutic agent for the treatment of estrogen receptor-positive (ER+) breast cancer. The compound demonstrates high purity and enantiomeric excess, and its synthesis involves chiral resolution and advanced reduction techniques. As a SERD, YZD-7082B works by binding to the estrogen receptor and promoting its degradation, thereby inhibiting estrogen-driven tumor growth[1][10].

Targets

ER (Estrogen receptor)

Beyond the preview

Go deeper on YZD-7082B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YZD-7082B.

Explore the full profile